Ozone-Based Agent

Phase 3Small molecule

UUniversity of Baghdad

Ozone-Based Agent is one of 23 small molecule programs targeting Keratitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeratitisActive, not recruiting

KeratitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

55 competitors in Keratitis

#DrugCompanyPhaseTrials

Neoral

Avelox

Rayos

Levaquin

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—6

Decadron

AAspen Global Incorporated

Acthar

1 8

OXERVATE

DDompé Farmaceutici S.p.A

Approved

1 9

Cenegermin

DDompé Farmaceutici S.p.A

Approved

1 10

Oxervate

DDompé Farmaceutici S.p.A

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Third Molar1 trial

the Effect of Ozone Oil on the Postoperative Sequalae After Surgical Removal of Third Molar

Completed·UUniversity of Baghdad·Phase 2·NCT05544539·40 enrolled

Keratitis1 trial

Ozone-based Eye Drops as Adjuvant Therapy in Microbial Keratitis

Unknown status·—·Phase 3·NCT05689996·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ozone-Based Agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ozone-Based Agent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ozone-Based Agent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Baghdad company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Baghdad

Ozone-Based Agent

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Third Molar1 trial

Keratitis1 trial

References

Drug Info

Quick Facts

Related News